Wide Ranks

BSX

Boston Scientific Corporation

90.75

Top Statistics
Market Cap 133 B Forward PE 32.53 Revenue Growth 19.30 %
Current Ratio 1.48 Trailing PE 75.00 Earnings Growth -6.30 %
Profit Margins 11.26 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 35.13 Enterprise / Revenue 8.97 Price To Sales Trailing12 Months 8.41
Profitability
Profit Margins 11.26 % Operating Margins 17.06 %
Balance Sheet
Total Cash 2 B Total Cash Per Share 1.70 Total Debt 11 B
Total Debt To Equity 53.72 Current Ratio 1.48 Book Value Per Share 14.05
All Measures
Short Ratio 157.00 % Message Board Id finmb_317627 Shares Short Prior Month 11 M
Return On Equity 0.0892 City Marlborough Uuid 69b49f65-05eb-36c8-ab80-d5db1263e17a
Previous Close 90.21 First Trade Date Epoch Utc 706 M Book Value 14.05
Beta 0.7970 Total Debt 11 B Volume 2 M
Price To Book 6.46 Last Split Date 1 B Fifty Two Week Low 53.93
Total Cash Per Share 1.70 Total Revenue 15 B Shares Short Previous Month Date 1 B
Target Median Price 98.00 Max Age 86400 Recommendation Mean 1.55
Sand P52 Week Change 0.3133 Operating Margins 17.06 % Target Mean Price 97.00
Net Income To Common 1 B Ask 90.73 Short Percent Of Float 0.0075
Implied Shares Outstanding 1 B Last Fiscal Year End 1 B Trailing Peg Ratio 164.52 %
Average Daily Volume10 Day 6 M Average Volume10days 6 M Total Cash 2 B
Next Fiscal Year End 1 B Revenue Per Share 10.83 Held Percent Insiders 0.0017
Ebitda Margins 25.54 % Trailing PE 75.00 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 90.21 Target Low Price 83.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 86.42 Open 90.40
Free Cashflow 1 B State MA Dividend Yield 0.00 %
Return On Assets 0.0490 Time Zone Short Name EST Trailing Eps 1.21
Day Low 90.08 Address1 300 Boston Scientific Way Shares Outstanding 1 B
Price Hint 2 Target High Price 110.00 Website https://www.bostonscientific.com
52 Week Change 0.6237 Average Volume 6 M Earnings Quarterly Growth -7.10 %
Forward Eps 2.79 Recommendation Key buy Compensation As Of Epoch Date 1 B
Quick Ratio 84.70 % Last Split Factor 2:1 Regular Market Day High 91.02
Is_sp_500 True Profit Margins 11.26 % Debt To Equity 53.72
Fifty Two Week High 91.93 Day High 91.02 Shares Short 11 M
Regular Market Open 90.40 Industry Key medical-devices Bid 90.70
Earnings Growth -6.30 % Enterprise To Revenue 8.97 Revenue Growth 19.30 %
Shares Percent Shares Out 0.0075 Operating Cashflow 2 B Currency USD
Time Zone Full Name America/New_York Market Cap 133 B Is_nasdaq_100 False
Zip 01752-1234 Quote Type EQUITY Industry Medical Devices
Long Name Boston Scientific Corporation Regular Market Day Low 90.08 Held Percent Institutions 0.9249
Current Price 90.75 Enterprise To Ebitda 35.13 Financial Currency USD
Current Ratio 1.48 Gross Margins 68.75 % Industry Disp Medical Devices
Number Of Analyst Opinions 31 Country United States Float Shares 1 B
Two Hundred Day Average 76.93 Ir Website http://phx.corporate-ir.net/phoenix.zhtml?c=62272&p=irol-irhome Enterprise Value 142 B
Price To Sales Trailing12 Months 8.41 Forward PE 32.53 Regular Market Volume 2 M
Ebitda 4 B Exchange NYQ
Go to Yahoo Finance Go to Seeking Alpha 
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide.

It operates through two segments, MedSurg and Cardiovascular.

The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems.

In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer.

The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.